Trial of BCG Immunotherapy in the Treatment of Resectable Squamous Cell Carcinoma of the Bronchus (Stages I and II)

  • P. Pouillart
  • G. Mathé
  • T. Palangie
  • L. Schwarzenberg
  • P. Huguenin
  • P. Morin
  • H. Gautier
  • A. Baron
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 62)

Abstract

Squamous cell carcinoma of the lung ranks as one of the most prevalent and lethal of all malignancies. Though bronchogenic carcinoma responds to both chemotherapy [10] and radiotherapy, the survival of lung cancer patients has not greatly increased, and cure is anticipated only when complete surgical resection is possible; under actual therapeutical conditions, no more than 7.5–10% of patients with squamous cell carcinoma of the lung can be cured, and chemotherapy systematically applied after surgery has been demonstrated as ineffective [1, 11].

Keywords

Leukemia Mycobacterium Endoxan 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brunner, K. W., Marhaler, T. H., Muller, W.: Unfavorable effects of long term adjuvant chemotherapy with endoxan in radically operated bronchogenic carcinoma. Europ. J. Cancer 7, 285–288 (1971).CrossRefGoogle Scholar
  2. 2.
    Decroix, J.: Personal communication.Google Scholar
  3. 3.
    Eilber, F. R., Morton, D. L.: Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 25, 362, 367 (1970).Google Scholar
  4. 4.
    Israel, L., Mugica, J., Cha Inian, P.: Prognosis of early bronchogenic carcinoma. Survival curves of 451 patients after resection of lung cancer in relation to the results of preoperative tuberculin skin tests. Biomedicine 19, 68–71 (1973).PubMedGoogle Scholar
  5. 5.
    Mathé, G., Amiel, J. L., Schwarzenberg, L., Cattan, A., Schlumberger, J. R., Hayat, M., de Vassal, F.: Active immunotherapy for acute lymphoid leukemia. Lancet (1969) I, 697–699.CrossRefGoogle Scholar
  6. 6.
    Mathé, G., Pouillart, P., Lapeyraque, F.: Active immunotherapy of L1210 leukemia applied after the graft of tumor cell. Brit. J. Cancer 23, 814–816 (1969).PubMedCrossRefGoogle Scholar
  7. 7.
    Mathé, G., Pouillart, P., Schwarzenberg, L., Amiel, J. L., Schneider, M., Hayat, M., de Vassal, F., Jasmin, C., Rosenfeld, C., Weiner, R., Rappaport, H.: Attempt at immunotherapy of 100 acute lymphoid leukemia patients. Some factors influencing results. Nat. Cancer Inst. 35, 361–371 (1972).Google Scholar
  8. 8.
    Morton, D. L., Eilber, F. R., Marmgren, R. A., Wood, W.: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158–164 (1970).PubMedGoogle Scholar
  9. 9.
    Pouillart, P., Botto, G., Gautier, H., Huguenin, P., Baron, A., Laparre, C., Hoang Thy, H. T., Parrot, R., Mathé, G.: Relation entre l’état immunitaire et la réponse à la chimiothérapie. Résultats chez 64 malades avec cancers bronchiques epidermoides inopérables. Nouv. Presse Med. 5, 1037–1042 (1976).PubMedGoogle Scholar
  10. 10.
    Pouillart, P., Schwarzenberg, L., Amiel, J. L., Mathé, G., Huguenin, P., Morin, P., Baron, A., Laparre, C., Parrot, C.: Combinaisons de drogues se potentialisant. 1. Application au traitement des cancers du sein. 2. Application au traitement des cancers des bronches. 3. Application au traitement des tumeurs primitives du système nerveux central. Nouv. Presse Med. 4, 713–716 (1975).PubMedGoogle Scholar
  11. 11.
    Selawry, O. S., Hansen, H. H.: Lung cancer in “cancer treatment.” Holland, J., Frei, E., III (eds.). Philadelphia: Lea and Febiger, 1974.Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1977

Authors and Affiliations

  • P. Pouillart
  • G. Mathé
  • T. Palangie
  • L. Schwarzenberg
  • P. Huguenin
  • P. Morin
  • H. Gautier
  • A. Baron

There are no affiliations available

Personalised recommendations